Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
Catalyst Pharmaceuticals (Nasdaq: CPRX) said President and CEO Rich Daly and other executives will participate in the Bank of America CNS Therapeutics Virtual Conference on Monday, December 8, 2025 at 12:35pm ET.
The session will be available via webcast on the company investor website at www.catalystpharma.com, and a replay will be accessible for at least 30 days after the presentation.
Catalyst Pharmaceuticals (Nasdaq: CPRX) ha detto che il presidente e amministratore delegato Rich Daly e altri dirigenti parteciperanno alla Bank of America CNS Therapeutics Virtual Conference lunedì 8 dicembre 2025 alle 12:35 p.m. ET.
La sessione sarà disponibile tramite webcast sul sito degli investitori dell'azienda all'indirizzo www.catalystpharma.com, e una riproduzione sarà accessibile per almeno 30 giorni dopo la presentazione.
Catalyst Pharmaceuticals (Nasdaq: CPRX) dijo que el presidente y director ejecutivo Rich Daly y otros ejecutivos participarán en la Bank of America CNS Therapeutics Virtual Conference el lunes 8 de diciembre de 2025 a las 12:35 p.m. ET.
La sesión estará disponible vía webcast en el sitio web de inversores de la empresa en www.catalystpharma.com, y una repetición estará accesible durante al menos 30 días después de la presentación.
Catalyst Pharmaceuticals (Nasdaq: CPRX)는 사장 겸 최고경영자 Rich Daly 및 다른 경영진들이 2025년 12월 8일 월요일에 오후 12:35 ET에 열리는 Bank of America CNS Therapeutics Virtual Conference에 참여할 것이라고 밝혔습니다.
세션은 회사 투자자 웹사이트 www.catalystpharma.com에서 생중계로 시청 가능하며 발표 후 최소 30일 동안 다시 보기가 제공됩니다.
Catalyst Pharmaceuticals (Nasdaq : CPRX) a déclaré que le président et directeur général Rich Daly et d'autres cadres participeront à la conférence virtuelle Bank of America CNS Therapeutics le lundi 8 décembre 2025 à 12 h 35 HNE.
La session sera disponible via webcast sur le site des investisseurs de l'entreprise à l'adresse www.catalystpharma.com, et une rediffusion sera accessible pendant au moins 30 jours après la présentation.
Catalyst Pharmaceuticals (Nasdaq: CPRX) teilte mit, dass Präsident und Geschäftsführer Rich Daly sowie weitere Führungskräfte an der virtuellen Bank of America CNS Therapeutics-Konferenz am Montag, dem 8. Dezember 2025 um 12:35 Uhr ET teilnehmen werden.
Die Sitzung ist über Webcast auf der Investorenseite des Unternehmens unter www.catalystpharma.com verfügbar, und eine Wiederholung wird nach der Präsentation mindestens 30 Tage lang zugänglich sein.
Catalyst Pharmaceuticals (Nasdaq: CPRX) ذكرت أن الرئيس التنفيذي Rich Daly وقيادات تنفيذية أخرى سيشاركون في مؤتمر Bank of America CNS Therapeutics الافتراضي يوم الاثنين 8 ديسمبر 2025 في الساعة 12:35 ظهراً بتوقيت شرق الولايات المتحدة.
ستتوفر الجلسة عبر البث على موقع الشركة للمستثمرين على www.catalystpharma.com, وسيكون بالإمكان الوصول إلى إعادة العرض لمدة لا تقل عن 30 يوماً بعد العرض.
- None.
- None.
CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Monday, December 8, 2025.
Date of Presentation: Monday, December 8, 2025
Time: 12:35pm ET
Webcast Link
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull or Olipriya Das, Russo Partners (858) 717-2310, 646 942 5588 david.schull@russopartnersllc.com, Olipriya.das@russopartnersllc.com